EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 17c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.33), $0.17 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $7.86 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Investing.com’s stocks of the week
• Dollarama Inc. (DOL:CN) (DLMAF) PT Raised to Cdn$221 at BMO Capital